US EditionPublished • loading... • Updated
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
Verzenio reduced death risk by 15.8% and cut metastatic disease by 32% over seven years in high-risk early breast cancer patients, monarchE trial data show.
- Eli Lilly presented seven-year monarchE results at the ESMO cancer congress and in Annals of Oncology showing two years of Verzenio improved overall survival to 86.8% versus 85% with endocrine therapy alone.
- The results will form the basis for regulatory filings to seek a label extension, as Eli Lilly aims to keep Verzenio ahead of Novartis's Kisqali, which won FDA approval last year based on the NATALEE trial.
- MonarchE results reveal specific risk reductions including 15.8% lower death risk and 32% less metastasis at seven years with 6.4% on Verzenio versus 9.4% on endocrine therapy.
- Commercially, the drug's sales picture shows $3 billion in 2024 sales and a 60% rise to $2.1 billion in H1 2025, with Verzenio’s 2021 approval driving more than $5 billion a year.
- Investigators and rapporteurs framed the findings cautiously, noting OS `continues to show an encouraging trend,' and Stephen Johnston emphasized `For patients, survival is what matters most,' while Angela DeMichele called for longer follow-up.
Insights by Ground AI
15 Articles
15 Articles
These days, the European Congress of Oncology will present the promising results of the abemaciclib trial in patients at high risk of breast cancer recurrence.
·Madrid, Spain
Read Full Article
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
(MedPage Today) -- BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed. Patients who received...
·New York, United States
Read Full Article
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early...
·United States
Read Full Article
Coverage Details
Total News Sources15
Leaning Left1Leaning Right0Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
L 20%
C 80%
Factuality
To view factuality data please Upgrade to Premium
